Increasing Clinical Virulence in Two Decades of the Italian HIV Epidemic

The recent origin and great evolutionary potential of HIV imply that the virulence of the virus might still be changing, which could greatly affect the future of the pandemic. However, previous studies of time trends of HIV virulence have yielded conflicting results. Here we used an established methodology to assess time trends in the severity (virulence) of untreated HIV infections in a large Italian cohort. We characterized clinical virulence by the decline slope of the CD4 count (n = 1423 patients) and the viral setpoint (n = 785 patients) in untreated patients with sufficient data points. We used linear regression models to detect correlations between the date of diagnosis (ranging 1984–2006) and the virulence markers, controlling for gender, exposure category, age, and CD4 count at entry. The decline slope of the CD4 count and the viral setpoint displayed highly significant correlation with the date of diagnosis pointing in the direction of increasing virulence. A detailed analysis of riskgroups revealed that the epidemics of intravenous drug users started with an apparently less virulent virus, but experienced the strongest trend towards steeper CD4 decline among the major exposure categories. While our study did not allow us to exclude the effect of potential time trends in host factors, our findings are consistent with the hypothesis of increasing HIV virulence. Importantly, the use of an established methodology allowed for a comparison with earlier results, which confirmed that genuine differences exist in the time trends of HIV virulence between different epidemics. We thus conclude that there is not a single global trend of HIV virulence, and results obtained in one epidemic cannot be extrapolated to others. Comparison of discordant patterns between riskgroups and epidemics hints at a converging trend, which might indicate that an optimal level of virulence might exist for the virus.

[1]  Roel A. Coutinho,et al.  Time from HIV-1 seroconversion to Aids and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis: collaborative Group on Aids incubation and HIV survival including the CASCADE EU concerted action , 2000 .

[2]  A. Lapedes,et al.  Timing the ancestor of the HIV-1 pandemic strains. , 2000, Science.

[3]  R. Raiteri,et al.  Is the clinical course of HIV-1 changing? Cohort study , 1997, BMJ.

[4]  D. Pillay,et al.  The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy , 2006, AIDS.

[5]  R. Hogg,et al.  Impact of Neighborhood-Level Socioeconomic Status on HIV Disease Progression in a Universal Health Care Setting , 2008, Journal of acquired immune deficiency syndromes.

[6]  J. Phair,et al.  Evaluation of secular trends in CD4+ lymphocyte loss among human immunodeficiency virus type 1 (HIV-1)-infected men with known dates of seroconversion. , 1995, American journal of epidemiology.

[7]  J. S. Sullivan,et al.  Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients , 1995, Science.

[8]  Giovanni Rezza,et al.  Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985–2002 , 2005, AIDS.

[9]  J. Kaldor,et al.  HIV infection in recipients of blood products from donors with known duration of infection , 1994, The Lancet.

[10]  S. Lawn AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. , 2004, The Journal of infection.

[11]  G. Rutherford,et al.  The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. , 1989, The New England journal of medicine.

[12]  I. Thior,et al.  Human immunodeficiency virus type 1 subtypes differ in disease progression. , 1999, The Journal of infectious diseases.

[13]  Gayathri Athreya,et al.  Unequal Evolutionary Rates in the Human Immunodeficiency Virus Type 1 (HIV-1) Pandemic: the Evolutionary Rate of HIV-1 Slows Down When the Epidemic Rate Increases , 2007, Journal of Virology.

[14]  Sebastian Bonhoeffer,et al.  Stable virulence levels in the HIV epidemic of Switzerland over two decades , 2006, AIDS.

[15]  D. Vlahov,et al.  Recent infection with human immunodeficiency virus and possible rapid loss of CD4 T lymphocytes. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[16]  E. Domingo,et al.  Molecular Basis for a Lack of Correlation between Viral Fitness and Cell Killing Capacity , 2007, PLoS pathogens.

[17]  E. Arts,et al.  Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time , 2005, AIDS.

[18]  S. Roberts,et al.  GB virus C: insights into co-infection. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[19]  Jacques Fellay,et al.  A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.

[20]  P. Vanhems,et al.  Association between the rate of CD4+ T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study. , 1999, The Journal of infectious diseases.

[21]  T. Déirdre Hollingsworth,et al.  Variation in HIV-1 set-point viral load: Epidemiological analysis and an evolutionary hypothesis , 2007, Proceedings of the National Academy of Sciences.

[22]  Scott Wegner,et al.  Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[24]  A. Phillips,et al.  Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. , 2007, The Journal of infectious diseases.

[25]  G. Touloumi Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion , 2003 .

[26]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[27]  J. Margolick,et al.  Lack of Evidence for Changing Virulence of HIV-1 in North America , 2008, PloS one.

[28]  E. Arts,et al.  Is HIV-1 evolving to a less virulent form in humans? , 2007, Nature Reviews Microbiology.

[29]  Michael J. Crawley,et al.  The R book , 2022 .

[30]  M. Prins,et al.  Differences in CD4 Cell Counts at Seroconversion and Decline Among 5739 HIV-1–Infected Individuals with Well-Estimated Dates of Seroconversion , 2003, Journal of acquired immune deficiency syndromes.

[31]  Ben Berkhout,et al.  Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. , 2007, Virology.

[32]  I. Keet,et al.  Temporal trends of the natural history of HIV-1 infection following seroconversion between 1984 and 1993. , 1996, AIDS.